Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Human monocytic colony-stimulating factor].

K Motoyoshi1

  • 1Division of Hemopoiesis, Institute of Hematology, Jichi Medical School.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1989
PubMed
Summary

Human monocytic colony-stimulating factor (hM-CSF) accelerates recovery from chemotherapy-induced neutropenia and thrombopenia. Unlike other CSFs, hM-CSF did not increase leukemic cell counts, showing potential for cancer patient treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

M-CSF attenuates severity of chronic GVHD after unrelated BMT.

Bone marrow transplantation·2011
Same author

IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation.

Cell death and differentiation·2010
Same author

BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.

Leukemia·2009
Same author

GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.

Neurology·2008
Same author

GD1b-specific antibody induces ataxia in Guillain-Barre syndrome.

Neurology·2008
Same author

Intrabullous blood injection for lung volume reduction.

Thorax·2008

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Context:

  • Cancer chemotherapy often leads to myelosuppression, increasing risks of infection and bleeding.
  • Existing colony-stimulating factors (CSFs) like G-CSF and GM-CSF can sometimes increase leukemic cell counts.
  • Human monocytic colony-stimulating factor (hM-CSF) is a glycoprotein with demonstrated effects on monocyte production and activity.

Purpose:

  • To evaluate the efficacy and safety of human monocytic colony-stimulating factor (hM-CSF) in mitigating chemotherapy-induced myelosuppression.
  • To compare the effects of hM-CSF with other CSFs on leukemic cell counts.
  • To assess the potential of hM-CSF as a therapeutic agent for cancer patients undergoing chemotherapy.

Summary:

  • hM-CSF stimulates monocyte production and enhances their tumor-killing activity against various leukemic cell lines.
  • Clinical studies showed hM-CSF infusions accelerated recovery from neutropenia and thrombopenia post-chemotherapy for hematological, gynecologic, and urogenital malignancies.
  • Importantly, hM-CSF infusions were well-tolerated and did not increase leukemic cell counts, unlike some other CSFs.

Impact:

  • hM-CSF demonstrates a favorable safety profile and efficacy in managing chemotherapy-induced side effects.
  • It offers a potential therapeutic strategy to improve patient outcomes by reducing myelosuppression.
  • The distinct lack of leukemic cell count increment positions hM-CSF as a promising agent for supportive care in oncology.

Related Experiment Videos